Navigation Links
Damon Runyon and Doris Duke Foundations announce partnership to support physician-scientists
Date:7/1/2010

New York, NY, July 1, 2010 The Damon Runyon Cancer Research Foundation (DRCRF) and the Doris Duke Charitable Foundation (DDCF) are pleased to announce their partnership in supporting an early career physician-scientist. Tobias J.E. Carling, MD, PhD, Assistant Professor of Surgery at the Yale University School of Medicine has been named as the first Doris Duke-Damon Runyon Clinical Investigator.

Dr. Carling will receive a total of $486,000 over three years for his project "Molecular Genetics of Endocrine Tumor Disease" (see below for lay summary). In addition, DRCRF will retire up to $100,000 of any qualifying outstanding medical school debt still owed by Dr. Carling.

It is a great honor to receive the Doris Duke-Damon Runyon Clinical Investigator Award for my research and scientific career development and to be supported by two of the most prestigious private medical research foundations in the country, said Dr. Carling.

The Damon Runyon and Doris Duke Foundations support young physician-scientists through similar grant programs, the Clinical Investigator Award and Clinical Scientist Development Award, respectively. Dr. Carling was recommended to receive each of these awards following rigorous independent peer review processes by both Foundations.

"There is a significant shortage of talented physician-scientists dedicated to translating research from the laboratory to the patient's bedside in search of breakthrough treatments," said Lorraine Egan, Executive Director of the Damon Runyon Cancer Research Foundation. "Both Foundations are highly committed to encouraging the careers of these unique individuals."

"We're delighted to be partnering with the Damon Runyon Cancer Research Foundation to fund Dr. Carling's project," said Ed Henry, president of the Doris Duke Charitable Foundation. "This award allows Dr. Carling the financial and professional benefits of being affiliated with both DDCF and DRCRF."

Lay Summary of Research

Dr. Carling focuses on endocrine tumors, a type of cancer which affects hormone-producing tissues in the body (such as the thyroid, pituitary gland, adrenal gland and islet cells of the pancreas). The underlying genetic basis for endocrine tumors is not yet known. Dr. Carling's goal is to complete a comprehensive genomic analysis of patients with endocrine tumor disease in order to identify individual genes involved in early cancer formation. His research will provide important insights into the development of endocrine tumors as well as other cancer types, laying the basis for future individualized medical and surgical management of cancer.

Dr. Carling works under the mentorship of Richard P. Lifton, MD, PhD, and Robert Udelsman, MD, MBA.


'/>"/>

Contact: Yung S. Lie, PhD
yung.lie@damonrunyon.org
212-455-0521
Damon Runyon Cancer Research Foundation
Source:Eurekalert

Related medicine news :

1. Three Pioneering Ideas in Cancer Research Granted Prestigious Damon Runyon-Rachleff Innovation Awards
2. Crown Works Dental Laboratory hosts CE Course by Dr. Damon C. Adams, Editor -In -Chief of Dentistry Today
3. Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators
4. Now Live! The “Safe Handling Dance” Video to Benefit ASHP/ONS Foundations
5. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
6. Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange
7. Pluromed Announces Completion of Enrollment in LeGoo™ Cardiac Bypass Clinical Trial
8. New Speakers Announced for the 2010 Personalized Medicine Partnerships Conference
9. Nuvo Research announces early redemption of 5% convertible debentures
10. Royal Caribbean International and LimoRes.com Announce Exclusive Partnership
11. China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... TX (PRWEB) , ... April 21, 2017 , ... ... Care products, announced an exciting new partnership with the highly regarded and well ... Airway Management’s highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will ...
(Date:4/21/2017)... Malvern, Worcestershire, UK (PRWEB) , ... April 21, ... ... Queen’s Award for Enterprise in the category of International Trade, the UK’s most ... performance in international trade, which represents 95% of total revenues and has grown ...
(Date:4/21/2017)... Ramon, CA (PRWEB) , ... April 21, 2017 , ... ... might not understand the estate planning process, or where to even begin. “Now more ... unresolved if you are to properly protect yourself and your family,” said attorney Lisa ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Westside Dental ... personalized dental care since 1985. After thirty-two years, Dr. Latner has become one of ... help my numerous clients over the years with all their dental needs,” said Dr. ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Each year, ... is a day to clean, plant trees and look forward to a better future. ... just about doing something outdoors. Indoor air quality can be two to five times ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
Breaking Medicine Technology: